Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are considered promising treatment candidates for NAFLD and NASH and are indicated for the treatment of type 2 diabetes and obesity [37]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.